|
Patient demographics
|
|
Male
|
19 (70.4%)
|
|
Female
|
8 (29.6%)
|
|
Age (years), mean ± SD (range)
|
43 ± 14.0 (27–70)
|
|
Exposure history
|
|
Exposure to positive patients
|
11 (40.7%)
|
|
Unknown exposure
|
16 (59.3%)
|
|
Comorbid conditions
|
|
Diabetes
|
6 (22.2%)
|
|
Hypertension
|
3 (11.1%)
|
|
Renal failure
|
3 (11.1%)
|
|
COPD
|
1 (3.7%)
|
|
Liver disease
|
1 (3.7%)
|
|
Signs and symptoms
|
|
No obvious symptoms
|
4 (14.8%)
|
|
Fever
|
19 (70.4%)
|
|
Dry cough
|
24 (88.9%)
|
|
SOB
|
6 (22.2%)
|
|
Myalgia
|
18 (66.6%)
|
|
Sore throat
|
16 (59.3%)
|
|
Headache
|
5 (18.5%)
|
|
Diarrhea
|
4 (14.8%)
|
|
Vomit
|
4 (14.8%)
|
|
Nausea
|
2 (7.4%)
|
|
Laboratory test
|
|
C-reactive protein (mg/L; normal range 0–10)
|
|
Increased
|
21 (77.8%)
|
|
Decreased
|
0 (0%)
|
|
Normal
|
4 (14.8%)
|
|
Leukocytes (normal range 4–10 × 109/L)
|
|
Increased
|
2 (7.4%)
|
|
Decreased
|
4 (14.8%)
|
|
Normal
|
21 (77.8%)
|
|
Lymphocytes (normal range 20–40%)
|
|
Increased
|
0 (0%)
|
|
Decreased
|
21 (77.8%)
|
|
Normal
|
6 (22.2%)
|
|
Neutrophils (normal range 50–70%)
|
|
Increased
|
19 (70.4%)
|
|
Decreased
|
0 (0%)
|
|
Normal
|
8 (29.6%)
|
